文献速递治疗药物监测与药物基因组学特殊人群用药

利用QSP模型进行模型引导精准给药:华法林/INR案例研究

Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR.
PubMed 文献 · Clin Pharmacol Ther · 2024-04-24

本研究基于凝血QSP模型衍生的华法林/INR机制模型,在外部数据集中评估其用于MIPD的预测性能,并与经验性参考模型比较。结果显示该模型预测性能与参考模型相当,纳入CYP2C9和/或VKORC1基因型可改善预测质量,门诊INR变异更高且预测略偏高。

要点

  • QSP衍生的华法林/INR模型在MIPD中预测性能与经验参考模型相当。
  • 纳入CYP2C9和/或VKORC1基因型可改善模型预测质量。
  • 门诊INR变异更高且预测略偏高,场景转换时或需调整模型。

核心结论

  • QSP衍生的华法林/INR模型在未用华法林起始数据校准的情况下,预测性能与经验参考模型相当。
  • 纳入CYP2C9和/或VKORC1基因型作为协变量可改善华法林/INR模型的预测质量。
  • 门诊INR的不可解释变异更高,预测值略高于观测值,提示从住院向门诊转换时可能需要模型调整。

研究设计与样本

  • 研究使用外部数据集评估华法林/INR模型在MIPD背景下的预测性能,数据来自开始华法林治疗患者的INR数据。
  • 评估模型预测的准确度和精确度,并以经验性参考模型作为基准进行比较。
  • 还评估了协变量贡献,并单独评估了更具挑战性的门诊数据的预测性能。

主要发现

  • 华法林/INR模型在多种指标上与参考模型表现相当,尽管未用华法林起始数据校准。
  • 纳入CYP2C9和/或VKORC1基因型作为协变量改善了预测质量,即使在纳入4天INR数据后仍改善。
  • 门诊INR表现出更高的不可解释变异,预测值略超过观测值。

临床怎么用

  • QSP衍生模型可作为MIPD的补充方法,与经验模型开发并行。
  • 在华法林MIPD中可考虑将CYP2C9和/或VKORC1基因型作为协变量纳入模型。
  • 住院向门诊转换时需注意模型预测可能偏高,必要时调整模型。

局限性

  • QSP模型复杂且缺乏临床数据验证,适用性存疑。
  • 门诊INR不可解释变异更高,模型在门诊场景的预测略偏高。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Warfarin dosing remains challenging due to substantial inter-individual variability, which can lead to unsafe or ineffective therapy with standard dosing. Model-informed precision dosing (MIPD) can help individualize warfarin dosing, requiring the selection of a suitable model. For models developed from clinical data, the dependence on the study design and population raises questions about generalizability. Quantitative system pharmacology (QSP) models promise better extrapolation abilities; however, their complexity and lack of validation on clinical data raise questions about applicability in MIPD. We have previously derived a mechanistic warfarin/international normalized ratio (INR) model from a blood coagulation QSP model. In this article, we evaluated the predictive performance of the warfarin/INR model in the context of MIPD using an external dataset with INR data from patients starting warfarin treatment. We assessed the accuracy and precision of model predictions, benchmarked against an empirically based reference model. Additionally, we evaluated covariate contributions and assessed the predictive performance separately in the more challenging outpatient data. The warfarin/INR model performed comparably to the reference model across various measures despite not being calibrated with warfarin initiation data. Including CYP2C9 and/or VKORC1 genotypes as covariates improved the prediction quality of the warfarin/INR model, even after assimilating 4 days of INR data. The outpatient INR exhibited higher unexplained variability, and predictions slightly exceeded observed values, suggesting that model adjustments might be necessary when transitioning from an inpatient to an outpatient setting. Overall, this research underscores the potential of QSP-derived models for MIPD, offering a complementary approach to empirical model development.

来源:Clin Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Falkenhagen U, Cavallari LH, Duarte JD, et al. Leveraging QSP Models for MIPD: A Case Study for Warfarin/INR. Clin Pharmacol Ther. 2024. PMID: 38655898. doi:10.1002/cpt.3274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。